J Clin Oncol: The safety and efficacy of Amivantamab in the treatment of platinum-based non-small cell lung cancer with exon 20 insertion mutations: the results of the initial analysis of the phase I study CHRYSALIS

EGFR mutation is a common driver gene in non-small cell lung cancer (NSCLC), and 85% of the mutations are the deletion of exon 19 or the point mutation of exon 21 and L858R

EGFR mutation is a common driver gene in non-small cell lung cancer (NSCLC), and 85% of the mutations are the deletion of exon 19 or the point mutation of exon 21 and L858R

From May 27, 2016 to June 8, 2020, 362 patients were enrolled

From May 27, 2016 to June 8, 2020, 362 patients were enrolled

Among the effective population (n=81 cases), the median age was 62 years (range, 42-84 years), 48 cases (59%) were women, 40 cases (49%) were Asian population, and all patients had received platinum As the basis for chemotherapy

In the assessment of safety population (n=114), adverse events (AEs) related to EGFR inhibition occurred in 98 patients (86%), 51 patients (45%) with paronychia, and 24 patients (21%) with stomatitis ), 19 cases of itching (17%), and 14 cases (12%) of diarrhea

Adverse events

Common grade 3-4 adverse events were hypokalemia (5%), skin rash (4%), pulmonary embolism (4%), diarrhea (4%), and neutropenia (4%)

Common grade 3-4 adverse events were hypokalemia (5%), skin rash (4%), pulmonary embolism (4%), diarrhea (4%), and neutropenia (4%)

The objective response rate (ORR) was 40% (95% CI, 29 to 51), including 3 cases of complete remission (CR) and 29 cases of partial remission (PR)

In summary, Amivantamab has shown good anti-tumor activity and safety in the treatment of platinum-based non-small cell lung cancer (NSCLC) patients with EGFR 20 exon insertion mutations

Original source:

Park K, Haura EB, Leighl NB, et al.

Park K, Haura EB, Leighl NB, et al.
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
J Clin Oncol.
2021 Aug 2: JCO2100662 .
doi: 10.
1200/JCO.
21.
00662.
Epub ahead of print.
PMID: 34339292.


Leave a message here